InMed Pharmaceuticals (INM) has released an update.
InMed Pharmaceuticals has entered into a Standby Equity Purchase Agreement with Yorkville Advisors, allowing it to sell up to $10 million of its common shares over a 36-month period. This financial strategy provides InMed with flexibility to raise capital as needed, supporting the acceleration of its pharmaceutical programs.
For further insights into INM stock, check out TipRanks’ Stock Analysis page.